SCHEMBL680225

SCHEMBL680225

Fc1cc(Br)ccc1Oc1cc2cnn(C3CCCCO3)c2cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
SCN9A Q15858 2/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
MAPK8 P45983 4/20 0.35
GHSR Q92847 3/20 0.34
MAPK14 Q16539 6/20 0.34
KCNH2 Q12809 1/20 0.34
GAK O14976 1/20 0.33
RPS6KA4 O75676 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680860 0.88 RXRA (0.43) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31411431 0.82 RXRA (0.46) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL679462 0.81 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL17588934 0.80 RXRA (0.48) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680191 0.80 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL2144301 0.80 RXRA (0.50) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29756229 0.80 RXRA (0.50) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL658009 0.80 RXRA (0.58) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29363930 0.80 RXRA (0.52) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL21797086 0.78 RXRA (0.48) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.